Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) and Sharps Technology (NASDAQ:STSS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.
Risk & Volatility
Capricor Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Sharps Technology has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500.
Institutional and Insider Ownership
21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 17.2% of Sharps Technology shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Comparatively, 1.2% of Sharps Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Capricor Therapeutics | 1 | 0 | 9 | 0 | 2.80 |
| Sharps Technology | 1 | 0 | 0 | 0 | 1.00 |
Capricor Therapeutics presently has a consensus price target of $48.36, indicating a potential upside of 65.97%. Given Capricor Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Capricor Therapeutics is more favorable than Sharps Technology.
Profitability
This table compares Capricor Therapeutics and Sharps Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Capricor Therapeutics | N/A | -59.27% | -48.65% |
| Sharps Technology | N/A | -157.91% | -154.40% |
Earnings & Valuation
This table compares Capricor Therapeutics and Sharps Technology”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Capricor Therapeutics | $22.27 million | 75.77 | -$105.04 million | ($2.32) | -12.56 |
| Sharps Technology | $396,900.00 | 196.20 | -$282.50 million | ($1.63) | -1.13 |
Capricor Therapeutics has higher revenue and earnings than Sharps Technology. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.
Summary
Capricor Therapeutics beats Sharps Technology on 9 of the 13 factors compared between the two stocks.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
About Sharps Technology
Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
